Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03075527 · OUTCOME

Median Progression Free Survival (PFS)

A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma · Source last updated 2026-07-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
80% Confidence Interval
Time frame
Participants were evaluated for response every 8 weeks on study and in long-term survival followed-up every 3-4 months. Median follow-up for survival is of 27.33 months with range (0.76 months - 50.40 months).

What was measured

PFS based on the Kaplan-Meier method is defined as the duration between randomization and documented disease progression (PD) defined per RECIST 1.1 criteria. or death, or is censored at time of last disease assessment.

Analysis population: The analysis population is comprised of eligible and treated patients.

Groups in this outcome

Tremelimumab + Durvalumab

Subjects will receive durvalumab and tremelimumab both via intravenous infusion once per day for every 28 day cycles (+ 7 days). Participants will receive tremelimumab for up to 4 cycles (4 doses). Beginning with cycle 5 day 1, subjects will continue to receive durvalumab alone, until clinical or radiological progression. Tremelimumab: Tremelimumab blocks a receptor on immune cells that normally suppresses immune attack. Durvalumab: Durvalumab is a drug that blocks a protein often produced by cancer cells or surrounding cells to suppress immune cells from attacking cancer cells.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Tremelimumab + Durvalumab19

Reported measurements

Source class 1
Values in months · Interval/dispersion: 80% Confidence Interval
GroupValueSpreadLowerUpperComment
Tremelimumab + Durvalumab3.42Not reported2.795.72Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        2.79
        upper Limit
        5.72
        value
        3.42
denoms
  1. counts
    1. group Id
      OG000
      value
      19
    units
    Participants
description
PFS based on the Kaplan-Meier method is defined as the duration between randomization and documented disease progression (PD) defined per RECIST 1.1 criteria. or death, or is censored at time of last disease assessment.
dispersion Type
80% Confidence Interval
groups
  1. description
    Subjects will receive durvalumab and tremelimumab both via intravenous infusion once per day for every 28 day cycles (+ 7 days). Participants will receive tremelimumab for up to 4 cycles (4 doses). Beginning with cycle 5 day 1, subjects will continue to receive durvalumab alone, until clinical or radiological progression. Tremelimumab: Tremelimumab blocks a receptor on immune cells that normally suppresses immune attack. Durvalumab: Durvalumab is a drug that blocks a protein often produced by cancer cells or surrounding cells to suppress immune cells from attacking cancer cells.
    id
    OG000
    title
    Tremelimumab + Durvalumab
param Type
MEDIAN
population Description
The analysis population is comprised of eligible and treated patients.
reporting Status
POSTED
time Frame
Participants were evaluated for response every 8 weeks on study and in long-term survival followed-up every 3-4 months. Median follow-up for survival is of 27.33 months with range (0.76 months - 50.40 months).
title
Median Progression Free Survival (PFS)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice